Septerna, Inc.
SEPN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001984086
In the last 90 days, Septerna, Inc. insiders filed 0 open-market purchases and 8 sales; 153 institutions reported holding it in 13F filings for Q2 2026, worth $1.59B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $72.5M in total
- 8
- 13F holdersQ2 2026, +31 vs. previous quarter
- 153
- 13F valueReported value at the end of Q2 2026
- $1.59B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding SEPN, Q2 2026
No superinvestor reported holding SEPN at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Septerna, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 (view filing)7:01 PM ET | Sep 1 | 2 days | Long Daniel D.SVP, Drug Discovery | SSale | −3.33K | $37.83 | −$126.1K | −3.3%96.4K after | 10b5-1 |
| Aug 14, 2026 (view filing)5:44 PM ET | Aug 12 | 2 days | Third Rock Ventures V, L.P. and 5 others10% Owner | SSale | +147.2K | $50.27 | +$7.40M | +2.5%6.07M after | 2 lots10b5-1 |
| Aug 14, 2026 (view filing)5:11 PM ET | Aug 12 | 2 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | SSale | −1.49M | $42.50 | −$63.5M | −67.3%725.4K after | 2 lots |
| Aug 13, 2026 (view filing)7:00 PM ET | Aug 11 | 2 days | Bhatt ElizabethPresident and COO | SSale | −25.0K | $44.00 | −$1.10M | −12.5%174.2K after | 10b5-1 |
| Aug 5, 2026 (view filing)7:00 PM ET | Aug 3 | 2 days | Long Daniel D.SVP, Drug Discovery | SSale | −3.33K | $34.47 | −$114.9K | −3.3%96.4K after | 2 lots10b5-1 |
| Jul 17, 2026 (view filing)7:00 PM ET | Jul 15 | 2 days | Bhatt ElizabethPresident and COO | SSale | −4.00K | $33.99 | −$136.0K | −2.2%174.2K after | 10b5-1 |
| Jul 2, 2026 (view filing)7:00 PM ET | Jul 1 | 1 day | Long Daniel D.SVP, Drug Discovery | SSale | −3.33K | $34.36 | −$114.5K | −3.3%96.4K after | 2 lots10b5-1 |
| Jun 30, 2026 (view filing) | Jun 29 | 1 day | Shaikhly SamiraChief People Officer | SSale | −2.18K | $35.18 | −$76.6K | −73.3%793 after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Long Daniel D.SVP, Drug Discovery | SSale | −15.0K | $35.51 | −$532.6K | −13.5%96.4K after | 2 lots10b5-1 |
| Jun 16, 2026 (view filing) | Jun 12 | 4 days | Shaikhly SamiraChief People Officer | SSale | −6.25K | $35.08 | −$219.3K | −88.7%793 after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Septerna, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 6,995,858 | $234.3M | 2.04% | 00.0% | Unchanged |
| TRV GP V, LLC | 6,215,591 | $208.2M | 41.78% | 00.0% | Unchanged |
| Driehaus Capital Management LLC | 4,433,058 | $148.5M | 0.86% | +37,486+0.9% | Added |
| TRV GP VI, LLC | 4,211,659 | $141.0M | 60.72% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 3,149,128 | $105.5M | 8.66% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 3,062,766 | $102.6M | 0.01% | +156,339+5.4% | Added |
| BlackRock, Inc. | 1,932,088 | $64.7M | 0.00% | +109,914+6.0% | Added |
| Siren, L.L.C. | 1,900,000 | $63.6M | 1.29% | −100,000−5.0% | Reduced |
| Avoro Capital Advisors LLC | 1,337,500 | $44.8M | 0.40% | 00.0% | Unchanged |
| Jupiter Topco LLC | 1,307,500 | $43.7M | 0.02% | +1,307,500 | New |